JMP Securities, which is part of JMP Group, an investment banking and alternative asset manager, has named Shawn Cross as managing director in its healthcare investment banking group. Previously, he was was chairman and CEO of GT Biopharma.
SAN FRANCISCO–(BUSINESS WIRE)–JMP Group LLC (NYSE: JMP), an investment banking and alternative asset management firm, announced today that Shawn Cross has joined JMP Securities as a managing director in its healthcare investment banking group. Based in the firm’s San Francisco office, Mr. Cross will concentrate on the biotechnology and biopharmaceutical sectors.
“Shawn brings over two decades of experience to JMP Securities’ healthcare group,” said Carter Mack, president of JMP Group. “He has held senior investment banking positions at top Wall Street firms and has also spent time in executive roles in industry. Shawn’s extensive knowledge of the biotech and biopharma spaces, as well as the associated capital markets and M&A landscapes, will help position our highly regarded life sciences franchise for even greater success.”
Prior to joining JMP Securities, Mr. Cross was chairman and chief executive officer of GT Biopharma, a clinical-stage immuno-oncology company. Mr. Cross was previously a managing director in healthcare investment banking at Deutsche Bank Securities, where he led the biotechnology coverage effort, after working as a managing director and head of biopharmaceutical investment banking at Well Fargo Securities. Earlier, Mr. Cross served in healthcare investment banking roles at Thomas Weisel Partners and Alex. Brown & Sons. Before commencing his Wall Street career, he performed cell cycle cancer research in the division of gastroenterology at University of Washington Medical School. Mr. Cross holds an MBA from Columbia Business School and a BS from University of California, Los Angeles.
JMP Securities is a full-service, middle-market investment bank with a healthcare platform consisting of six investment banking calling officers, a senior healthcare capital markets professional, and six equity research analysts covering biotechnology, biopharmaceuticals, medical devices and supplies, and healthcare services and facilities. The firm’s healthcare investment banking group executed 38 capital raising and strategic advisory transactions with an aggregate value of $4.1 billion in 2017 and has completed 35 such transactions in 2018 to date.
About JMP Group
JMP Group LLC is a diversified capital markets firm that provides investment banking, equity research, and sales and trading services to corporate and institutional clients as well as alternative asset management products and services to institutional and high-net-worth investors. JMP Group conducts its investment banking and research, sales and trading activities through JMP Securities; its hedge fund, venture and private capital, and credit management activities through Harvest Capital Strategies, JMP Asset Management and JMP Credit Advisors; and the management of Harvest Capital Credit Corporation (NASDAQ: HCAP), a business development company, through HCAP Advisors. For more information, visit www.jmpg.com.